Serum Tumor Markers in Esophageal Cancer: Current Evidence

Serum tumor markers are substances measured in blood that may reflect tumour activity. In oesophageal cancer, commonly studied markers include carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag), CYFRA 21-1, carbohydrate antigen 19-9 (CA19-9) and CA72-4. Their potential roles include supporting diagnosis, estimating prognosis and tracking treatment response.

The evidence remains limited and uneven. A raised result can occur with other cancers, inflammation, liver disease or smoking, while a normal result does not exclude oesophageal malignancy. For clinicians and patients in Australia, blood markers are best viewed as supplementary information alongside endoscopy, biopsy, staging scans and multidisciplinary review. The educational resources associated with the ISDE 2021 congress provide useful context for how these questions were discussed by international specialists.

What the main markers indicate

CEA is the most familiar marker in gastrointestinal oncology, yet its performance in oesophageal cancer is modest. It may be elevated in adenocarcinoma, particularly when disease is advanced, but sensitivity is insufficient for population screening or diagnosis. Smoking can also increase CEA, which complicates interpretation in a country where tobacco exposure remains clinically relevant.

SCC-Ag is more closely associated with squamous cell carcinoma, while CYFRA 21-1 measures a fragment of cytokeratin 19. Studies suggest that elevated SCC-Ag or CYFRA 21-1 may correlate with tumour burden, lymph-node involvement or poorer survival. CA19-9 and CA72-4 have also been investigated, although results vary between studies and laboratories. None has demonstrated the accuracy needed to replace tissue diagnosis.

Where blood tests fit in care

A blood marker should not be used as a stand-alone diagnostic test for persistent dysphagia, odynophagia, unexplained weight loss or food obstruction. In Australia, a patient seen in a Sydney, Melbourne or regional gastroenterology service would generally require upper endoscopy with biopsy, followed by imaging such as CT and PET-CT when appropriate. Endoscopic ultrasound can help assess local invasion and regional nodes.

Before treatment, a baseline marker may be useful if it is clearly elevated. Repeating the same assay during chemotherapy, immunotherapy or chemoradiation can show whether the level falls in parallel with clinical response. However, a change in concentration should be interpreted with scans, symptoms and nutritional status. A single increase is not proof of progression, and a falling result does not establish complete response.

Comparing commonly studied markers

The usefulness of a marker depends on histological subtype, disease stage, assay quality and the clinical question. Results from research cohorts cannot always be transferred directly into routine practice, particularly when studies use different cut-off values or include small patient groups.

A combined panel may improve sensitivity in research settings, but it can reduce specificity and create false alarms. Broad testing also adds cost and may prompt unnecessary scans or invasive procedures. Australian laboratories operate under accreditation requirements, yet clinicians still need to confirm that serial results come from a comparable assay and reference range.

Evidence for prognosis and surveillance

Meta-analyses often find that persistently elevated CEA, SCC-Ag or CYFRA 21-1 is associated with advanced stage, nodal disease or shorter survival. These associations are clinically interesting because they may help identify patients who need closer assessment. They do not, however, prove that changing the marker itself improves outcomes.

After surgery or definitive chemoradiation, surveillance is usually guided by symptoms, examination, endoscopy and imaging rather than routine blood-marker testing alone. Australian practice also varies according to whether care is delivered through a public hospital, private oncology network or a rural referral pathway. Travel from regional New South Wales or Queensland to a tertiary centre can affect appointment timing, so a simple blood test may be convenient, but convenience should not be mistaken for diagnostic reliability.

Newer approaches are being studied, including circulating tumour DNA, methylated DNA fragments and circulating tumour cells. These liquid-biopsy methods may detect molecular residual disease earlier than conventional markers, but they remain under evaluation and are not yet interchangeable with validated staging tools. Tissue biomarkers such as HER2, mismatch-repair status and PD-L1 are also important for treatment selection, but they are assessed primarily in tumour tissue rather than serum.

Practical interpretation for Australian patients

A result should be considered in context: tumour subtype, stage, smoking history, liver function, infection, treatment timing and the laboratory method all matter. Medicare-funded testing rules and local pathology policies may differ from private arrangements, while access to specialist interpretation can be harder in remote areas. Patients should receive a clear explanation of whether a test is being used for baseline assessment, monitoring or research.

The strongest current position is cautious. Serum markers may add information when a marker was raised before treatment and changes consistently over time, but they cannot screen the general population, confirm oesophageal cancer or replace endoscopy and imaging. Research presented through professional forums, including international oesophageal disease meetings, continues to refine their role.

What the reader should remember is that a blood marker is an adjunct, not a verdict: the diagnosis and treatment plan depend on pathology, staging investigations and coordinated specialist care.